Pregnancy and infant outcomes following abatacept exposure during pregnancy
Rheumatology Advances in Practice · 15.06.2026 · 10 (3)
DOI: 10.1093/rap/rkag084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 20.07.2026. Verfasst von Christina D Chambers und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BMS.
Abstract (Originalsprache)
Objectives
Abatacept is approved for the treatment of moderate–severe RA, JIA and PsA in the USA and elsewhere. The purpose of this study was to estimate the incidence/birth prevalence of selected maternal and infant outcomes in pregnancies exposed to abatacept.
Methods
Pregnant women exposed to any dose of abatacept from the first day of the last menstrual period to the end of the first trimester who resided in the USA or Canada were enrolled in the Organization of Teratology Information Specialists Abatacept Pregnancy Exposure Registry between 2007 and 2019. Data on exposures, outcomes and covariates were collected by maternal interviews, medical records and study-related physical examinations up to 1 year postpartum.
Results
The sample consisted of 30 abatacept-exposed pregnancies. Sixteen were enrolled prospectively and were treated for RA or PsA; 14 did not meet the prospective criteria and were enrolled in an exposure series. Of those prospectively enrolled, 2/13 (15.4%) involved an infant with a major birth defect, 2/16 (12.5%) ended in spontaneous abortion and 2/13 (15.4%) delivered preterm. In the exposure series, 5/14 livebirths (35.7%) ended with an infant with a major birth defect, 2 of which were chromosomal or genetic, and 6/14 (42.9%) delivered preterm.
Conclusion
There were no patterns of major or minor birth defects identified in either group. In the exposure series, selected adverse outcomes were more frequent, likely due to biases that led to exclusion of these pregnancies from the prospective cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA.
- Department of Mathematics, University of California San Diego, La Jolla, CA, USA.
- Deparment of Pediatrics, Saint Louis University, St. Louis, MO, USA.
- Department of Pediatrics, University of Washington, Seattle, WA, USA.
- Department of Pediatrics, State University of New York Buffalo School of Medicine, Buffalo, NY, USA.
Förderung
- BMS
Zitieren
APA
Chambers, C. D., Caesar, M. A., Johnson, D. L., Xu, R., Luo, Y., Braddock, S. R., Adam, M. P., Robinson, L. K., Lyons Jones, K., OTIS Collaborative Research Group, & OTIS Collaborative Research Group (2026). Pregnancy and infant outcomes following abatacept exposure during pregnancy. Rheumatology Advances in Practice, 10(3). https://doi.org/10.1093/rap/rkag084
Vancouver
Chambers CD, Caesar MA, Johnson DL, Xu R, Luo Y, Braddock SR, et al. Pregnancy and infant outcomes following abatacept exposure during pregnancy. Rheumatology Advances in Practice. 2026;10(3). doi:10.1093/rap/rkag084
BibTeX
@article{Chambers2026,
author = {Chambers, Christina D and Caesar, Michelle Ann and Johnson, Diana L and Xu, Ronghui and Luo, Yunjun and Braddock, Stephen R and Adam, Margaret P and Robinson, Luther K and Lyons Jones, Kenneth and OTIS Collaborative Research Group, OTIS Collaborative Research Group and OTIS Collaborative Research Group, OTIS Collaborative Research Group},
title = {Pregnancy and infant outcomes following abatacept exposure during pregnancy},
journal = {Rheumatology Advances in Practice},
year = {2026},
volume = {10},
number = {3},
doi = {10.1093/rap/rkag084}
}
EUVIMED